ArrowMark Colorado Holdings’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.3M | Sell |
316,956
-16,746
| -5% | -$742K | 0.41% | 73 |
|
|
2025
Q4 | $13.8M | Sell |
333,702
-6,925
| -2% | -$278K | 0.3% | 98 |
|
|
2025
Q3 | $13.2M | Sell |
340,627
-125,272
| -27% | -$4.07M | 0.25% | 108 |
|
|
2025
Q2 | $12.9M | Sell |
465,899
-69,808
| -13% | -$1.78M | 0.23% | 113 |
|
|
2025
Q1 | $11.9M | Buy |
535,707
+13,818
| +3% | +$284K | 0.19% | 113 |
|
|
2024
Q4 | $10.3M | Sell |
521,889
-9,397
| -2% | -$214K | 0.14% | 134 |
|
|
2024
Q3 | $13.3M | Sell |
531,286
-77,582
| -13% | -$1.89M | 0.17% | 122 |
|
|
2024
Q2 | $11.4M | Sell |
608,868
-58,108
| -9% | -$1.09M | 0.14% | 127 |
|
|
2024
Q1 | $13.2M | Sell |
666,976
-47,903
| -7% | -$936K | 0.15% | 126 |
|
|
2023
Q4 | $12.5M | Sell |
714,879
-45,474
| -6% | -$747K | 0.14% | 129 |
|
|
2023
Q3 | $13.2M | Sell |
760,353
-224,843
| -23% | -$3.79M | 0.16% | 117 |
|
|
2023
Q2 | $13.9M | Buy |
985,196
+98,326
| +11% | +$1.32M | 0.15% | 126 |
|
|
2023
Q1 | $9.54M | Buy |
886,870
+169,699
| +24% | +$2.24M | 0.11% | 145 |
|
|
2022
Q4 | $10.7M | Sell |
717,171
-210,923
| -23% | -$3.07M | 0.13% | 138 |
|
|
2022
Q3 | $11.9M | Sell |
928,094
-223,043
| -19% | -$2.54M | 0.15% | 129 |
|
|
2022
Q2 | $11.2M | Sell |
1,151,137
-169,840
| -13% | -$1.58M | 0.13% | 147 |
|
|
2022
Q1 | $13.1M | Buy |
1,320,977
+47,928
| +4% | +$508K | 0.11% | 155 |
|
|
2021
Q4 | $15M | Buy |
1,273,049
+38,399
| +3% | +$472K | 0.12% | 145 |
|
|
2021
Q3 | $14.1M | Buy |
1,234,650
+374,776
| +44% | +$4.88M | 0.11% | 154 |
|
|
2021
Q2 | $12M | Sell |
859,874
-10,548
| -1% | -$160K | 0.09% | 185 |
|
|
2021
Q1 | $16.1M | Sell |
870,422
-285,916
| -25% | -$5.85M | 0.12% | 141 |
|
|
2020
Q4 | $20.4M | Sell |
1,156,338
-2,963
| -0.3% | -$52K | 0.16% | 123 |
|
|
2020
Q3 | $17.8M | Buy |
+1,159,301
| New | +$21.8M | 0.17% | 110 |
|
|
2020
Q2 | – | Sell |
-1,274,424
| Closed | -$19.7M | – | 313 |
|
|
2020
Q1 | $19.7M | Sell |
1,274,424
-1,009,237
| -44% | -$15.8M | 0.26% | 93 |
|
|
2019
Q4 | $25.3M | Buy |
2,283,661
+238,153
| +12% | +$2.07M | 0.22% | 100 |
|
|
2019
Q3 | $17.4M | Buy |
2,045,508
+261,624
| +15% | +$2.89M | 0.17% | 110 |
|
|
2019
Q2 | $24.2M | Buy |
1,783,884
+173,703
| +11% | +$2.7M | 0.23% | 99 |
|
|
2019
Q1 | $29.1M | Buy |
+1,610,181
| New | +$31.1M | 0.27% | 92 |
|
|
2018
Q4 | – | Sell |
-1,192,424
| Closed | -$24.9M | – | 83 |
|
|
2018
Q3 | $26.5M | Buy |
1,192,424
+1,042,093
| +693% | +$20.3M | 0.22% | 105 |
|
|
2018
Q2 | $2.61M | Buy |
+150,331
| New | +$2.72M | 0.02% | 261 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
VPM
VCM
ArrowMark Colorado Holdings's KNSA Position: Q1 2026 in Review
ArrowMark Colorado Holdings reduced its Kiniksa Pharmaceuticals (KNSA) stake by 5% in Q1 2026, selling an estimated $742K and leaving 316,956 shares worth $15.3M. The position accounts for 0.41% of the portfolio, ranked #73.
ArrowMark Colorado Holdings first reported a position in KNSA in Q2 2018 and has held it in 30 quarters since. The position peaked at $29.1M in Q1 2019. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.
- ArrowMark Colorado Holdings held 316,956 shares of Kiniksa Pharmaceuticals worth $15.3M as of Q1 2026.
- ArrowMark Colorado Holdings sold 16,746 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $742K.
- Kiniksa Pharmaceuticals made up 0.41% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #73 holding.
- ArrowMark Colorado Holdings first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
- ArrowMark Colorado Holdings's Kiniksa Pharmaceuticals position peaked at $29.1M in Q1 2019.
- 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.
Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.